165 related articles for article (PubMed ID: 32360001)
1. Natural history and clinical outcomes of pancreatic neuroendocrine neoplasms based on the WHO 2017 classification; a single-center experience of 30 years.
Fujimori N; Miki M; Lee L; Matsumoto K; Takamatsu Y; Takaoka T; Teramatsu K; Suehiro Y; Murakami M; Igarashi H; Oono T; Ohtsuka T; Nakamura M; Koga Y; Oda Y; Ito T; Ogawa Y
Pancreatology; 2020 Jun; 20(4):709-715. PubMed ID: 32360001
[TBL] [Abstract][Full Text] [Related]
2. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
[TBL] [Abstract][Full Text] [Related]
3. Concordance Between the Ki-67 Index Cutoff Value of 55% and Differentiation in Neuroendocrine Tumor and Neuroendocrine Carcinoma in Grade 3 Pancreatic Neuroendocrine Neoplasms.
Shi H; Chen L; Zhang Q; Lin Y; Jiang C; Yao H; Hou X; Chen M; Lin R; Chen J
Pancreas; 2020; 49(10):1378-1382. PubMed ID: 33122528
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcome and long-term survival of 150 consecutive patients with pancreatic neuroendocrine tumors: A comprehensive analysis by the World Health Organization 2010 grading classification.
Deng BY; Liu F; Yin SN; Chen AP; Xu L; Li B
Clin Res Hepatol Gastroenterol; 2018 Jun; 42(3):261-268. PubMed ID: 29307515
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of tumour burden in stage IV neuroendocrine neoplasia: A comparison between pancreatic and gastrointestinal localizations.
Panzuto F; Pusceddu S; Faggiano A; Rinzivillo M; Brighi N; Prinzi N; Riccardi F; Iannicelli E; Maggio I; Femia D; Tafuto S; Manuzzi L; Di Sarno A; Annibale B; de Braud F; Campana D;
Pancreatology; 2019 Dec; 19(8):1067-1073. PubMed ID: 31587962
[TBL] [Abstract][Full Text] [Related]
6. World Health Organization grading classification for pancreatic neuroendocrine neoplasms: a comprehensive analysis from a large Chinese institution.
Yang M; Zeng L; Ke NW; Tan CL; Tian BL; Liu XB; Xiang B; Zhang Y
BMC Cancer; 2020 Sep; 20(1):906. PubMed ID: 32962649
[TBL] [Abstract][Full Text] [Related]
7. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
Tang LH; Basturk O; Sue JJ; Klimstra DS
Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
[TBL] [Abstract][Full Text] [Related]
8. Pancreatic High-Grade Neuroendocrine Neoplasms in the Korean Population: A Multicenter Study.
Kim H; An S; Lee K; Ahn S; Park DY; Kim JH; Kang DW; Kim MJ; Chang MS; Jung ES; Kim JM; Choi YJ; Jin SY; Chang HK; Cho MY; Kang YK; Kang M; Ahn S; Kim YW; Hong SM;
Cancer Res Treat; 2020 Jan; 52(1):263-276. PubMed ID: 31319641
[TBL] [Abstract][Full Text] [Related]
9. Machine learning-based model for prediction and feature analysis of recurrence in pancreatic neuroendocrine tumors G1/G2.
Murakami M; Fujimori N; Nakata K; Nakamura M; Hashimoto S; Kurahara H; Nishihara K; Abe T; Hashigo S; Kugiyama N; Ozawa E; Okamoto K; Ishida Y; Okano K; Takaki R; Shimamatsu Y; Ito T; Miki M; Oza N; Yamaguchi D; Yamamoto H; Takedomi H; Kawabe K; Akashi T; Miyahara K; Ohuchida J; Ogura Y; Nakashima Y; Ueki T; Ishigami K; Umakoshi H; Ueda K; Oono T; Ogawa Y
J Gastroenterol; 2023 Jun; 58(6):586-597. PubMed ID: 37099152
[TBL] [Abstract][Full Text] [Related]
10. Survival comparison between primary hepatic neuroendocrine neoplasms and primary pancreatic neuroendocrine neoplasms and the analysis on prognosis-related factors.
Li MX; Li QY; Xiao M; Wan DL; Chen XH; Zhou L; Xie HY; Zheng SS
Hepatobiliary Pancreat Dis Int; 2019 Dec; 18(6):538-545. PubMed ID: 30981633
[TBL] [Abstract][Full Text] [Related]
11. Sunitinib shrinks NET-G3 pancreatic neuroendocrine neoplasms.
Mizuno Y; Kudo A; Akashi T; Akahoshi K; Ogura T; Ogawa K; Ono H; Mitsunori Y; Ban D; Tanaka S; Tateishi U; Tanabe M
J Cancer Res Clin Oncol; 2018 Jun; 144(6):1155-1163. PubMed ID: 29602973
[TBL] [Abstract][Full Text] [Related]
12. A Clinicopathologic and Molecular Update of Pancreatic Neuroendocrine Neoplasms With a Focus on the New World Health Organization Classification.
Fang JM; Shi J
Arch Pathol Lab Med; 2019 Nov; 143(11):1317-1326. PubMed ID: 31509453
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
[TBL] [Abstract][Full Text] [Related]
14. Comparison of World Health Organization 2000/2004 and World Health Organization 2010 classifications for gastrointestinal and pancreatic neuroendocrine tumors.
Pasaoglu E; Dursun N; Ozyalvacli G; Hacihasanoglu E; Behzatoglu K; Calay O
Ann Diagn Pathol; 2015 Apr; 19(2):81-7. PubMed ID: 25702616
[TBL] [Abstract][Full Text] [Related]
15. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
[TBL] [Abstract][Full Text] [Related]
16. Gastric neuroendocrine neoplasias: manifestations and comparative outcomes.
Felder S; Jann H; Arsenic R; Denecke T; Prasad V; Knappe-Drzikova B; Maasberg S; Wiedenmann B; Pavel M; Pascher A; Pape UF
Endocr Relat Cancer; 2019 Sep; 26(9):751-763. PubMed ID: 31272081
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of intratumoral perfusion analysis for assessing biological features of non-functional pancreatic neuroendocrine neoplasm.
Notake T; Shimizu A; Kubota K; Sugenoya S; Umemura K; Goto T; Yamada A; Fujinaga Y; Soejima Y
Langenbecks Arch Surg; 2024 Jan; 409(1):38. PubMed ID: 38221590
[TBL] [Abstract][Full Text] [Related]
18. Calcitonin-Producing Neuroendocrine Neoplasms of the Pancreas: Clinicopathological Study of 25 Cases and Review of the Literature.
Uccella S; Blank A; Maragliano R; Sessa F; Perren A; La Rosa S
Endocr Pathol; 2017 Dec; 28(4):351-361. PubMed ID: 29063495
[TBL] [Abstract][Full Text] [Related]
19. Correlation of computed tomography imaging features and pathological features of 41 patients with pancreatic neuroendocrine tumors.
Utsumi M; Umeda Y; Takagi K; Takashi K; Nobuoka D; Yoshida R; Shinoura S; Sadamori H; Yagi T; Fujiwara T
Hepatogastroenterology; 2015; 62(138):441-6. PubMed ID: 25916078
[TBL] [Abstract][Full Text] [Related]
20. The number of positive nodes accurately predicts recurrence after pancreaticoduodenectomy for nonfunctioning neuroendocrine neoplasms.
Partelli S; Javed AA; Andreasi V; He J; Muffatti F; Weiss MJ; Sessa F; La Rosa S; Doglioni C; Zamboni G; Wolfgang CL; Falconi M
Eur J Surg Oncol; 2018 Jun; 44(6):778-783. PubMed ID: 29610023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
